Lupin Ltd — Q4 FY26
Lupin delivered a stellar Q4 FY26 with revenue of ₹7,475 crore (+32% YoY) and EBITDA of ₹2,171 crore (+68% YoY), marking the 15th consecutive quarter of growth.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
FY26 EBITDA margin guidance raised to 27-28%
Management raised full-year EBITDA margin guidance to 27-28% from earlier 25-26%, citing strong operational performance.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY26
R&D spend to remain 7.5-8.5% of sales
R&D expenditure is expected to stay in the 7.5-8.5% range going forward, with focus on complex generics and biosimilars.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1